ArticleBMC microbiology2026
Cepharanthine as a potential Fis inhibitor enhances Enrofloxacin efficacy against Pasteurella multocida.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPasteurella multocida, a primary bacterial pathogen responsible for bovine respiratory diseases, has developed resistance to multiple antibiotics, including fluoroquinolones, and is also an important zoonotic pathogen. Previous studies have demonstrated that Fis protein plays a critical role in bacterial virulence and antibiotic resistance formation. In resistant strains, Fis expression is upregulated and deletion of this gene significantly delays the development of fluoroquinolone resistance. Thus, Fis represents a potential target protein of antibiotic resistance inhibitors.
resultsThrough meticulous molecular docking and dynamics simulation studies, we have identified that cepharanthine as a potential inhibitor of Fis. The combination of cepharanthine and enrofloxacin successfully inhibits the development of fluoroquinolone resistance in Pasteurella multocida, with the fractional inhibitory concentration index indicating synergistic antimicrobial effect. Based on energy metabolism measurements and transcriptome sequencing analyses, we consider cepharanthine as a potential Fis inhibitor that may play a role in multiple biological processes of Pasteurella multocida regulated by Fis protein, resulting in a synergistic antibacterial response.
conclusionsCepharanthine is a potent Fis inhibitor and its combination with enrofloxacin presents a highly promising therapeutic approach for combatting Pasteurella multocida infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.